Popoca MMC, Henríquez MI, Méndez DA, Revilla BJ, Molina PA

Language: Spanish
References: 12
Page: 55-59
PDF size: 208.19 Kb.

ABSTRACT

Objective: The purpose of the study is to evaluate the effect of two years of therapy with human recombinant rHu-EPO in anemia in the patient with Chronic Renal Disease (CRD) in predialysis phase and its effects on the quality of life.
Patients and methods: 20 patients with CRD in predialysis phase were studied. Each one of these patients carried out every visit a complete blood count and blood chemistry; the scale of KDQOL was applied at visit 1 and at the final visit. The initial dose recommended was 50 UI/Kg of rHu-EPO, twice per week, administered by subcutaneous injection during the duration of study, scheduled for 24 months.
Results: The haemoglobin and hematocrit levels increased in all patients included in this project; in general, the quality of life improved in this group of patients compared from baseline.
Discussion: The recombinant human erhytropoietin in patients with chronic renal disease produces positive effects in its general state. We observed sensation of well-being, that is not only explained to correct the anemia, but by the global effect of the medicine.
Conclusions: human recombinant erhytropoietin in a long term produces satisfactory effects in the quality of life; therefore, he is useful in patients with anemia and chronic renal disease.

REFERENCES

1. Méndez DA, Barajas AR, Rivera RG, Méndez DE. Eficacia de la eritropoyetina humana recombinante en la corrección de la anemia en pacientes en fase de prediálisis y repercusión en la calidad de vida. Nefrol Mex 2004;25(1):15-20.

2. Jungers P, Choukroun G, Ovalin Z, Robino C, et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001;16:307-12.

3. Valderrábano F. Anaemia management in chronic kidney disease patients: an overview of current clinical practice. Nephrol Dial Transplant 2002;17(Suppl 1):S13-8.

4. Stivelman J. Benefits of anaemia tratment on cognitive function. Nephrol Dial Transplant. 2000;15(Suppl 3):S29-35.

5. Pickett J, Theberge D, Brown W, Schweitzer SU, Nissenson AR. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999;33:1122-30.

6. The Cochrane Database of Systematic reviews. The Cochrane Library. 2002.

7. Furuland H, Torbjörn L, Ahlmen J, Christensson A, et al. A randomized controlled trial of haemoglobin normalization with epoietin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003;18(2):353-61.

8. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 1999;14:1-50.

9. Valderrabano F. Quality of life benefits of early anaemia treatment. Nephrol Dial Transplant 2000;15(Suppl 3):S23-8.

10. McMahon LP, Mason K, Skinner SL, Burge CM, et al. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000;15:1425-30.

11. Ng T, Marx G, Littlewood T, Macdougall I. Recombinant erythropoietin in clinical practice. Postgrad Med J 2003;79:367-76.

12. NFK-DOQI. Clinical Practice Guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997;30(Suppl 3):S192-240.